Doctors from Mount Sinai and Sorrento Therapeutics will clone coronavirus survivors' antibodies to mass-produce a novel treatment.

Interesting EngineeringBy Brad Bergan

© busracavus / iStock | Doctors to Clone Antibodies of Coronavirus Survivors for New Treatment

Doctors and special medical researchers from Mount Sinai Health System and the pharmaceutical company Sorrento Therapeutics have joined forces to clone protective antibodies from coronavirus survivors and mass-produce the treatment, according to a Sorrento Therapeutics press release.
If all goes well, the "pharmaceutical cocktail" could be available by the end of the year, according to Futurism.

Doctors want to clone coronavirus survivors' antibodies for new treatment

The world needs a preventative treatment for the coronavirus, and doctors have enlisted thousands of coronavirus survivors, to clone their immune systems' antibodies and save countless people infected with the COVID-19 illness.
"We're working with pharma and biotech partners, such as Sorrento, to bring much-needed therapies to the clinic," said Mount Sinai Health System's Executive Vice President and Chief Commercial Innovation Officer Erik Lium. "We look forward to advancing the development of an effective antibody cocktail with Sorrento."
Once given to an as-yet uninfected person, the antibodies might strengthen their immune system against the coronavirus, not unlike a vaccine. Sorrento CEO Henry Ji thinks the forthcoming treatment might protect patients for up to two full months possibly better than a vaccine.
"A vaccine takes time to generate immunity and not everyone will respond to a vaccine, especially the elderly and immune-compromised patients," said Ji to Futurism. "A neutralizing antibody cocktail bypassed the need for a patient to respond to a vaccine and gives instant immunity upon injection."

COVID-19 treatment could be available this year

In partnership with Mount Sinai, Sorrento researchers will have access to 15,000 patients' blood samples, all of whom underwent coronavirus screening, courtesy of a diagnostic test developed by Florian Krammer, a microbiologist at Mount Sinai following an emergency use authorization from the FDA.
This article was originally published by Interesting Engineering. 
Previous Post Next Post